Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics centers on allegations that the company misrepresented the clinical efficacy of its Nanobody structure compared to traditional monoclonal antibodies, particularly in the context of the Phase 3 VELA trials [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that its product SLK shares the same molecular targets as BIMZELX, a competitor, which undermines its claimed competitive advantage [3]. - Allegations include that the company misrepresented the Nanobody's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Financial Impact - Investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and experienced significant losses are encouraged to participate in the lawsuit [4]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors in similar cases, indicating a strong potential for recovery [4][7]. Next Steps for Investors - The deadline for investors to move for appointment as lead plaintiff in the class action lawsuit is December 15, 2025 [1][5]. - Investors are urged to contact Hagens Berman for more information and to discuss their losses related to MoonLake [5][6].

Core Insights - The lawsuit against MoonLake Immunotherapeutics, Inc. alleges that the company concealed material adverse facts regarding the clinical performance of its drug SLK, particularly in comparison to competitors like BIMZELX [2][3] - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these alleged misrepresentations [3] Legal Allegations - The lawsuit focuses on the alleged failure of MoonLake to disclose that SLK shares the same molecular targets as BIMZELX, which could mislead investors about its competitive positioning [3] - It is claimed that MoonLake misrepresented the efficacy of its Nanobody structure, suggesting it would provide superior clinical outcomes for treating hidradenitis suppurativa [3] - The legal focus includes whether investors are entitled to damages due to the alleged wrongful acts and omissions during the class period [3] Investor Actions - Investors who purchased MLTX shares between March 10, 2024, and September 29, 2025, and suffered losses are encouraged to contact Hagens Berman for potential legal action [4] - The deadline for investors to move the court for appointment as lead plaintiff is December 15, 2025 [1][5] Firm Background - Hagens Berman has a strong track record, having secured over $2.9 billion in settlements for investors in similar cases [4][6] - The firm specializes in corporate accountability and represents various stakeholders, including investors and whistleblowers [6]